{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:11:09Z","timestamp":1772169069437,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/wellcomeopenres.20111.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000}}],"reference-count":65,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome","doi-asserted-by":"publisher","award":["209265"],"award-info":[{"award-number":["209265"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["wellcomeopenresearch.org"],"crossmark-restriction":false},"short-container-title":["Wellcome Open Res"],"abstract":"<ns4:p>\n                    Background Even on the best antimalarial treatments (injectable artesunate) African children with severe malaria have poor outcomes with most deaths occurring early in the course of hospital admission (&lt;24hours). Lactic acidosis, largely due to impairment of the microcirculatory flow due to parasite sequestration, is a main risk factor for poor outcome. There are no adjuvant treatments for severe malaria that target this complication. Sevuparin, a heparin-like drug, binds to\n                    <ns4:italic>Plasmodium falciparum<\/ns4:italic>\n                    erythrocyte membrane protein blocking merozoite invasion, preventing cytoadherence and transiently de-sequestering infected erythrocytes. Leading to improved microcirculatory flow by reversing\/preventing parasite sequestration. If given early during admission this could result in improvements in outcomes. Sevuparin has been shown to be safe and well tolerated in adults with only some mild transient effects on activated partial thromboplastin time (APTT) were reported, without clinical consequences. Methods A Phase I trial designed to provide data on safety, dosing, feasibility of sevuparin as an adjuvant therapy in Kenya and Zambian children with severe malaria complicated by lactic acidosis (&gt; 2mmol\/l). Three intravenous doses will be given at admission (0 hours), 8 and 16 hours. APPT will be measured 1 hour after each dose (to assess maximum toxicity). Studying 20 children will allow sufficient data on safety to be generated across a range of doses to identify the maximum tolerated dose (MTD) using the Continual Reassessment Method, which adapts or informs subsequent doses for each child based on the data from previously enrolled children. The MTD will be identified based on the dose-toxicity model updated by each previous patient\u2019s APTT results using standard methods. Conclusions The results of the Phase I trial will identify the final dose to be tested in a Phase II trial in terms of both efficacy and safety outcomes. Registration PACTR number: 202007890194806 (date 20\/07\/2020) ISRCTN32271864 (date 28\/07\/2021)\n                  <\/ns4:p>","DOI":"10.12688\/wellcomeopenres.20111.2","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T13:00:06Z","timestamp":1723467606000},"page":"484","update-policy":"https:\/\/doi.org\/10.12688\/wellcomeopenres.crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)"],"prefix":"10.12688","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-8109","authenticated-orcid":false,"given":"Kathryn","family":"Maitland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0266-1414","authenticated-orcid":false,"given":"Mainga","family":"Hamaluba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-4359","authenticated-orcid":false,"given":"Nchafatso","family":"Obonyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Oguda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christabel","family":"Mogoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4456-2382","authenticated-orcid":false,"given":"Thomas N.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Chaponda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Miti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc Kambale","family":"Kamavu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9007-2304","authenticated-orcid":false,"given":"Jonathan","family":"Jonathan Gwasupika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-4336","authenticated-orcid":false,"given":"Roisin","family":"Connon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-5490","authenticated-orcid":false,"given":"Diana M.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5190-2395","authenticated-orcid":false,"given":"Arjen","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2309-1171","authenticated-orcid":false,"given":"Nick","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-1978","authenticated-orcid":false,"given":"Nick","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Sarah","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Severe Malaria in African Children A Research and Trials (SMAART) consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"515-8","DOI":"10.1038\/nature24059","article-title":"The prevalence of Plasmodium falciparum in sub-Saharan Africa since 1900.","volume":"550","author":"R Snow","year":"2017","journal-title":"Nature."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"1739-47","DOI":"10.1016\/S0140-6736(13)62566-0","article-title":"The changing risk of Plasmodium falciparum malaria infection in Africa: 2000\u201310: a spatial and temporal analysis of transmission intensity.","volume":"383","author":"A Noor","year":"2014","journal-title":"Lancet."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"2532-4","DOI":"10.1016\/S0140-6736(17)33080-5","article-title":"The global fight against malaria is at crossroads.","volume":"390","author":"P Alonso","year":"2017","journal-title":"Lancet."},{"key":"ref-4","article-title":"World Malaria Report.","year":"2017"},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1647-57","DOI":"10.1016\/S0140-6736(10)61924-1","article-title":"Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.","volume":"376","author":"A Dondorp","year":"2010","journal-title":"Lancet."},{"key":"ref-6","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0263-6","article-title":"Management of severe paediatric malaria in resource-limited settings.","volume":"13","author":"K Maitland","year":"2015","journal-title":"BMC Med."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"2416-7","DOI":"10.1056\/NEJMp1613528","article-title":"Severe Malaria in African children - the need for continuing investment.","volume":"375","author":"K Maitland","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009964.pub2","article-title":"Pre-referral rectal artesunate for severe malaria.","volume":"2014","author":"J Okebe","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"997-1008","DOI":"10.1586\/eri.10.90","article-title":"Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria.","volume":"8","author":"C John","year":"2010","journal-title":"Expert Rev Anti Infect Ther."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1080-90","DOI":"10.1093\/cid\/cis034","article-title":"Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial.","volume":"54","author":"L von Seidlein","year":"2012","journal-title":"Clin Infect Dis."},{"key":"ref-11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-334","article-title":"Hypoglycaemia in severe malaria, clinical associations and relationship to quinine dosage.","volume":"10","author":"G Ogetii","year":"2010","journal-title":"BMC Infect Dis."},{"key":"ref-12","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-31","article-title":"Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review.","volume":"12","author":"J Church","year":"2014","journal-title":"BMC Med."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"939-46","DOI":"10.1093\/cid\/cix003","article-title":"High frequency of blackwater fever among children presenting to hospital with severe febrile illnesses in Eastern Uganda.","volume":"64","author":"P Olupot-Olupot","year":"2017","journal-title":"Clin Infect Dis."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"2483-95","DOI":"10.1056\/NEJMoa1101549","article-title":"Mortality after fluid bolus in African children with severe infection.","volume":"364","author":"K Maitland","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"407-19","DOI":"10.1056\/NEJMoa1900105","article-title":"Immediate transfusion in African children with uncomplicated severe anemia.","volume":"381","author":"K Maitland","year":"2019","journal-title":"N Engl J Med."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"420-31","DOI":"10.1056\/NEJMoa1900100","article-title":"Transfusion volume for children with severe anemia in Africa.","volume":"381","author":"K Maitland","year":"2019","journal-title":"N Engl J Med."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"566-76","DOI":"10.1007\/s00134-021-06385-3","article-title":"Randomised controlled trial of oxygen therapy and high-flow nasal therapy in African children with pneumonia.","volume":"47","author":"K Maitland","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"192-8","DOI":"10.1093\/infdis\/jit116","article-title":"Lethal malaria: Marchiafava and Bignami were right.","volume":"208","author":"N White","year":"2013","journal-title":"J Infect Dis."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"673-707","DOI":"10.1146\/annurev.micro.55.1.673","article-title":"Antigenic variation at the infected red cell surface in malaria.","volume":"55","author":"S Kyes","year":"2001","journal-title":"Annu Rev Microbiol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"439-50","DOI":"10.1128\/CMR.13.3.439","article-title":"Molecular aspects of severe malaria.","volume":"13","author":"Q Chen","year":"2000","journal-title":"Clin Microbiol Rev."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"228-32","DOI":"10.1016\/s0169-4758(00)01666-5","article-title":"Abnormal blood flow and red blood cell deformability in severe malaria.","volume":"16","author":"A Dondorp","year":"2000","journal-title":"Parasitol Today."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"79-84","DOI":"10.1086\/523762","article-title":"Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria.","volume":"197","author":"A Dondorp","year":"2008","journal-title":"J Infect Dis."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1742-6","DOI":"10.1086\/315078","article-title":"Cytokine expression in the brain in human cerebral malaria.","volume":"180","author":"H Brown","year":"1999","journal-title":"J Infect Dis."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"571-9","DOI":"10.1093\/infdis\/jis400","article-title":"Relative contributions of macrovascular and microvascular dysfunction to disease severity in falciparum malaria.","volume":"206","author":"J Hanson","year":"2012","journal-title":"J Infect Dis."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"788-93","DOI":"10.1093\/infdis\/jiv502","article-title":"Sequestration and red cell deformability as determinants of hyperlactatemia in falciparum malaria.","volume":"213","author":"H Ishioka","year":"2016","journal-title":"J Infect Dis."},{"key":"ref-26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169307","article-title":"Defining surrogate endpoints for clinical trials in severe falciparum malaria.","volume":"12","author":"A Jeeyapant","year":"2017","journal-title":"PLoS One."},{"key":"ref-27","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1014-x","article-title":"Lactate clearance as a prognostic marker of mortality in severely ill febrile children in East Africa.","volume":"16","author":"A Aramburo","year":"2018","journal-title":"BMC Med."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"663-71","DOI":"10.1093\/infdis\/jir812","article-title":"Sequestration and microvascular congestion are associated with coma in human cerebral malaria.","volume":"205","author":"M Ponsford","year":"2012","journal-title":"J Infect Dis."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"351-61","DOI":"10.1093\/infdis\/jis675","article-title":"Defining falciparum-malaria-attributable severe febrile illness in moderate-to-high transmission settings on the basis of plasma PfHRP2 concentration.","volume":"207","author":"I Hendriksen","year":"2013","journal-title":"J Infect Dis."},{"key":"ref-30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118898","article-title":"Binding of subdomains 1\/2 of PfEMP1-DBL1\u03b1 to heparan sulfate or heparin mediates Plasmodium falciparum rosetting.","volume":"10","author":"D Angeletti","year":"2015","journal-title":"PLoS One."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"3594-9","DOI":"10.1182\/blood.V95.11.3594","article-title":"The duffy-binding-like domain 1 of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a heparan sulfate ligand that requires 12 mers for binding.","volume":"95","author":"A Barragan","year":"2000","journal-title":"Blood."},{"key":"ref-32","first-page":"489-95","article-title":"Heparin in the treatment of cerebral malaria (a preliminary report).","volume":"16","author":"M Munir","year":"1976","journal-title":"Paediatr Indones."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"47-50","DOI":"10.14238\/pi20.1-2.1980.47-50","article-title":"Heparin in the treatment of Cerebral Malaria.","volume":"20","author":"M Munir","year":"1980","journal-title":"Paediatr Indones."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"608-12","DOI":"10.4269\/ajtmh.1991.45.608","article-title":"Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study.","volume":"45","author":"C Hemmer","year":"1991","journal-title":"Am J Trop Med Hyg."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1110-2","DOI":"10.1016\/s0140-6736(72)92716-x","article-title":"Ancrod, heparin, and -aminocaproic acid in simian Knowlesi malaria.","volume":"2","author":"H Reid","year":"1972","journal-title":"Lancet."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"167-8","DOI":"10.1016\/s0140-6736(75)91469-5","article-title":"Letter: Adjuvant treatment of severe falciparum malaria, intravascular coagulation, and heparin.","volume":"1","author":"H Reid","year":"1975","journal-title":"Lancet."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"595-602","DOI":"10.4269\/ajtmh.1992.46.595","article-title":"Disruption of Plasmodium falciparum erythrocyte rosettes by standard heparin and heparin devoid of anticoagulant activity.","volume":"46","author":"J Carlson","year":"1992","journal-title":"Am J Trop Med Hyg."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"589-94","DOI":"10.4269\/ajtmh.1992.46.589","article-title":"Effect of different fractions of heparin on Plasmodium falciparum merozoite invasion of red blood cells in vitro.","volume":"46","author":"A Kulane","year":"1992","journal-title":"Am J Trop Med Hyg."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"390-6","DOI":"10.4269\/ajtmh.2011.10-0256","article-title":"Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates.","volume":"84","author":"A Leitgeb","year":"2011","journal-title":"Am J Trop Med Hyg."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"7-131","DOI":"10.1111\/tmi.12313_2","article-title":"Severe malaria.","volume":"19 Suppl 1","year":"2014","journal-title":"Trop Med Int Health."},{"key":"ref-41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172718","article-title":"Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes.","volume":"12","author":"S Saiwaew","year":"2017","journal-title":"PLoS One."},{"key":"ref-42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188754","article-title":"Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria.","volume":"12","author":"A Leitgeb","year":"2017","journal-title":"PLoS One."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"e334-e43","DOI":"10.1016\/S2352-3026(21)00053-3","article-title":"Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"8","author":"B Biemond","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref-44","first-page":"1477-87","article-title":"Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity.","volume":"152","author":"G Turner","year":"1998","journal-title":"Am J Pathol."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"598-603","DOI":"10.1007\/BF00227452","article-title":"Serum levels of adhesion molecules and thrombomodulin as indicators of vascular injury in severe Plasmodium falciparum malaria.","volume":"72","author":"M Boehme","year":"1994","journal-title":"Clin Investig."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"457-64","DOI":"10.1055\/s-0038-1648889","article-title":"Elevated thrombomodulin plasma levels as a result of endothelial involvement in plasmodium falciparum malaria.","volume":"72","author":"C Hemmer","year":"1994","journal-title":"Thromb Haemost."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"686-91","DOI":"10.4269\/ajtmh.2002.66.686","article-title":"Prognostic value of thrombocytopenia in African children with falciparum malaria.","volume":"66","author":"P G\u00e9rardin","year":"2002","journal-title":"Am J Trop Med Hyg."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"839-47","DOI":"10.1046\/j.1365-2141.2002.03904.x","article-title":"Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome.","volume":"119","author":"S Ladhani","year":"2002","journal-title":"Br J Haematol."},{"key":"ref-49","first-page":"486-92","article-title":"Malaria at the university hospital and the St.-Clara hospital, Basel, in the period of 1970-1979.","volume":"76","author":"D Schmidt","year":"1983","journal-title":"Bull Soc Pathol Exot Filiales."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"762-6","DOI":"10.1016\/0035-9203(89)90321-0","article-title":"Activation of the coagulation cascade in falciparum malaria.","volume":"83","author":"S Pukrittayakamee","year":"1989","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"100-5","DOI":"10.1111\/j.1365-2141.1994.tb04877.x","article-title":"Activation of the coagulation cascade in severe falciparum malaria through the intrinsic pathway.","volume":"87","author":"R Clemens","year":"1994","journal-title":"Br J Haematol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"37-44","DOI":"10.1016\/0002-9343(91)90071-5","article-title":"Activation of the host response in human Plasmodium falciparum malaria: relation of parasitemia to tumor necrosis factor\/cachectin, thrombin-antithrombin III, and protein C levels.","volume":"91","author":"C Hemmer","year":"1991","journal-title":"Am J Med."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"1399-404","DOI":"10.1056\/NEJM199505253322102","article-title":"Indicators of life-threatening malaria in African children.","volume":"332","author":"K Marsh","year":"1995","journal-title":"N Engl J Med."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"218-21","DOI":"10.1016\/s0140-6736(72)90620-4","article-title":"Fibrin-degradation products in Cerebral Malaria.","volume":"1","author":"H Reid","year":"1972","journal-title":"Lancet."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"155-65","DOI":"10.1111\/j.1538-7836.2006.02232.x","article-title":"Plasmodium falciparum-infected erythrocytes induce Tissue Factor expression in Endothelial Cells and support the assembly of multimolecular coagulation complexes.","volume":"5","author":"I Francischetti","year":"2007","journal-title":"J Thromb Haemost."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"195-9","DOI":"10.4103\/1117-1936.180545","article-title":"Coagulation profile in Nigerian children with cerebral malaria.","volume":"13","author":"T Akingbola","year":"2006","journal-title":"Niger Postgrad Med J."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"842-51","DOI":"10.1182\/blood-2013-03-490219","article-title":"Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in Cerebral Malaria in African children.","volume":"122","author":"C Moxon","year":"2013","journal-title":"Blood."},{"key":"ref-58","article-title":"SPIRIT Checklist for \u2018SEVUparin as a potential Adjunctive Treatment in children with severe malaria: a Phase I trial safety and Dose Finding Trial (SEVUSMAART)\u2019.","author":"K Maitland","year":"2023"},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"57-71","DOI":"10.1191\/1740774506cn134oa","article-title":"The Continual Reassessment Method for dose-finding studies: a tutorial.","volume":"3","author":"E Garrett-Mayer","year":"2006","journal-title":"Clin Trials."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"426-34","DOI":"10.1111\/ijlh.12519","article-title":"Point-Of-Care PT and aPTT in patients with suspected deficiencies of coagulation factors.","volume":"38","author":"J Niederd\u00f6ckl","year":"2016","journal-title":"Int J Lab Hematol."},{"key":"ref-61","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-90","article-title":"Use of deferred consent for severely ill children in a multi-centre phase III trial.","volume":"12","author":"K Maitland","year":"2011","journal-title":"Trials."},{"key":"ref-62","article-title":"Sevuparin clinical trial: SEVUSMAAR.","author":"K Maitland","year":"2023"},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"217-26","DOI":"10.1179\/146532808X335679","article-title":"Monitoring psychomotor development in a resource-limited setting: an evaluation of the Kilifi Developmental Inventory.","volume":"28","author":"A Abubakar","year":"2008","journal-title":"Ann Trop Paediatr."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"1998-2005","DOI":"10.1182\/blood.V80.8.1998.1998","article-title":"Maturation of the hemostatic system during childhood.","volume":"80","author":"M Andrew","year":"1992","journal-title":"Blood."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"437-55","DOI":"10.1080\/10543400902800486","article-title":"Continual Reassessment Method vs. traditional empirically based design: modifications motivated by phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium.","volume":"19","author":"A Onar","year":"2009","journal-title":"J Biopharm Stat."}],"container-title":["Wellcome Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/8-484\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/8-484\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/8-484\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T02:35:10Z","timestamp":1724898910000},"score":1,"resource":{"primary":{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/8-484\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":65,"URL":"https:\/\/doi.org\/10.12688\/wellcomeopenres.20111.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/wellcomeopenres.20111.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.21956\/wellcomeopenres.25245.r93306","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/wellcomeopenres.25245.r93306","asserted-by":"object"}]},"ISSN":["2398-502X"],"issn-type":[{"value":"2398-502X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"Indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/8-484\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/wellcomeopenres.22271.r71475, Mei Li, National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, 02 Jan 2024, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/wellcomeopenresearch.org\/articles\/8-484\/v1#referee-response-71475","order":0,"name":"referee-response-71475","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Kathryn Maitland<\/b>; \n<i>Posted: 02 Aug 2024<\/i>; We thank the reviewer for a positive appraisal the the trial protocol. With regards to the question on measurement of parasite biomass using PfHRP2 there is a substantial literature on its superiority in estimating true biomass rather the parasitaemia. It was first described by the coauthors of this trial protocol. Of specific relevance to severe malaria, which results from extensive sequestration of parasitised erythrocytes, sequestered parasites secrete PfHRP2 into the plasma which is liberated at schizont rupture. The plasma concentration of PfHRP2 provide a better estimate for the patient's total parasite biomass, rather than peripheral parasitaemia (which assesses the less mature and pathogenic circulating stages (https:\/\/doi.org\/10.1371\/journal.pmed.0020204). In addition, PfHRP levels more accurately predict children who have true severe malaria from those with incidental parasitaemia, and is a better indicator of prognosis rather than parasitaemia (https:\/\/doi.org\/10.1093\/infdis\/jis675). We understand that low levels of HRP2 can persist even after clearance of malaria parasites. PfHRP in our study is being used to stratify risk at admission in children administered with severe and complicated disease.","URL":"https:\/\/wellcomeopenresearch.org\/articles\/8-484\/v2#referee-comment-5753","order":1,"name":"referee-comment-5753","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/wellcomeopenres.25245.r93306, Bruno Mmbando, Muhimbili University of Health and Allied Sciences, Dar es Salaam, 29 Aug 2024, version 2, indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/8-484\/v2#referee-response-93306","order":2,"name":"referee-response-93306","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The trial was supported by a Wellcome Collaborative Grant in Science [209265, <a href=https:\/\/doi.org\/10.35802\/209265>https:\/\/doi.org\/10.35802\/209265<\/a>]. MODUS Therapeutics AB, Olof Palmes v\u00e4g 29 IV, SE-111 22, Stockholm, Sweden provided Sevuparin for the trial. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}